becaplermin


Also found in: Wikipedia.

becaplermin

 [bĕ-kap´ler-min]
a recombinant platelet-derived growth factor used in treatment of chronic severe dermal ulcers of the lower limbs in diabetes mellitus.

becaplermin

/be·cap·ler·min/ (bĕ-kap´ler-min) a recombinant platelet-derived growth factor used in the treatment of chronic severe dermal ulcers of the lower limbs in diabetes mellitus.

becaplermin

[bĕ-kap′ler-min]
a recombinant platelet-derived growth factor used in treatment of chronic severe dermal ulcers of the lower limbs in diabetes mellitus.

becaplermin

A cicatrizant gel containing recombinant PDGF, which may improve wound healing—it stimulates migration of cells to ulcer sites, and prompts tissue growth to heal deep open wounds.
 
Indication
Diabetic foot ulcers.
 
Cons
Expensive, increased risk of cancer.

becaplermin

Recombinant human platelet-derived growth factor used to promote the healing of leg ulcers, especially in diabetics. A brand name is Regranex.
References in periodicals archive ?
Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
To read about Regranex and FDA's follow-up communication go to: Becaplermin (marketed as Regranex) Information Update of Safety Review: Follow-up to the March 27, 2008, Communication about the Ongoing Safety Review of Regranex (becaplermin)
Review of records during the phase III trials of becaplermin demonstrated that diabetic foot ulcers in treatment centers where debridements were performed most frequently were statistically more likely to heal than in centers performing the least frequent debridements[16] (Table 3).
In September 2012, the Company amended its PMA to include the results of a study conducted on becaplermin (Regranex([R])) to evaluate cancer mortality.
4) In addition to systemic therapy, local wound care with cleansing, use of antiseptic agents and certain specific agents like topical tacrolimus, hyauronic acid, becaplermin, lyophilized type I bovine collagen matrix have been used in few case reports.
Information about the increased risk of cancer-related deaths in patients who have used three or more tubes of becaplermin is now included in a boxed warning on the label of the diabetic foot and leg ulcer treatment.
Last month, the Food and Drug Administration announced that the warning had been added to the label of becaplermin (Regranex), a recombinant human platelet-derived growth factor that was approved in 1997.
The risk of death from cancer may be increased in patients prescribed becaplermin (Regranex) more than three times, according to a statement issued by the Food and Drug Administration.
The authors compared patients taking becaplermin with those who did not.
TABLE 24 GLOBAL BIOSIMILAR BECAPLERMIN MARKET, BY GEOGRAPHY 2007 - 2014 ($ THOUSANDS)
CHICAGO -- Diabetic neuropathic foot ulcers treated with becaplermin were 30% more likely to heal during a 20-week study period than ulcers not treated with the drug.
In a retrospective cohort study of 25,098 patients, 10% were treated with becaplermin (Regranex), a topical recombinant human platelet-derived growth factor (rhPDGF).